Загрузка...
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia
ABL tyrosine kinase inhibitors (TKIs) dramatically improves chronic myeloid leukemia (CML) prognosis and most CML patients are now able to lead lives that are equivalent to those of healthy individuals. However, high cost to CML patients of long-term treatment and adverse effects (AEs) remain proble...
Сохранить в:
| Опубликовано в: : | Stem Cell Investig |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
AME Publishing Company
2016
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4981735/ https://ncbi.nlm.nih.gov/pubmed/27583255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2016.07.08 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|